Definitive Healthcare (NASDAQ:DH) Updates FY 2026 Earnings Guidance

Key Points

• Definitive Healthcare issued FY 2026 guidance for EPS of $0.18–$0.20, above the $0.16 consensus estimate, while forecasting revenue of $220.0–$222.0 million, slightly below the $223.6 million consensus. Q3 2026 EPS guidance is $0.04–$0.05.
• Analyst sentiment remains cautious, with a consensus “Reduce” rating and an average price target of $1.88; the stock recently traded around $0.70 and remains near its 12-month low.
• The company beat its latest quarterly estimates, reporting $0.06 EPS and $55.93 million in revenue, while institutional investors and hedge funds collectively own 98.67% of its shares.

Definitive Healthcare (NASDAQ:DH - Get Free Report) issued an update on its FY 2026 earnings guidance on Monday morning. The company provided EPS guidance of 0.180-0.200 for the period, compared to the consensus EPS estimate of 0.160. The company issued revenue guidance of $220.0 million-$222.0 million, compared to the consensus revenue estimate of $223.6 million. Definitive Healthcare also updated its Q3 2026 guidance to 0.040-0.050 EPS.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the company. Wall Street Zen raised Definitive Healthcare from a "hold" rating to a "buy" rating in a report on Sunday, July 26th. Weiss Ratings reissued a "sell (e+)" rating on shares of Definitive Healthcare in a research report on Wednesday, June 3rd. Robert W. Baird set a $1.10 target price on shares of Definitive Healthcare in a report on Friday, May 8th. Bank of America reiterated an "underperform" rating and issued a $0.70 price target on shares of Definitive Healthcare in a research note on Monday, June 29th. Finally, Zacks Research upgraded shares of Definitive Healthcare from a "strong sell" rating to a "hold" rating in a research report on Tuesday, April 28th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Hold rating and four have given a Sell rating to the stock. According to MarketBeat.com, Definitive Healthcare currently has a consensus rating of "Reduce" and an average price target of $1.88.

Definitive Healthcare Price Performance

DH traded down $0.01 on Monday, hitting $0.70. 172,029 shares of the stock were exchanged, compared to its average volume of 358,377. The business has a 50-day moving average of $0.78 and a two-hundred day moving average of $1.12. The firm has a market capitalization of $73.71 million, a price-to-earnings ratio of -0.43, a PEG ratio of 11.51 and a beta of 1.35. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.75 and a quick ratio of 1.75. Definitive Healthcare has a 12 month low of $0.62 and a 12 month high of $4.35.

Definitive Healthcare (NASDAQ:DH - Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.06 EPS for the quarter, beating the consensus estimate of $0.03 by $0.03. The business had revenue of $55.93 million during the quarter, compared to the consensus estimate of $55.02 million. Definitive Healthcare had a negative net margin of 76.04% and a positive return on equity of 4.04%. Sell-side analysts forecast that Definitive Healthcare will post 0.04 EPS for the current fiscal year.

Institutional Trading of Definitive Healthcare

Hedge funds have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets increased its holdings in Definitive Healthcare by 32.9% in the third quarter. BNP Paribas Financial Markets now owns 17,811 shares of the company's stock worth $72,000 after purchasing an additional 4,407 shares in the last quarter. Invesco Ltd. boosted its holdings in shares of Definitive Healthcare by 5.8% during the 4th quarter. Invesco Ltd. now owns 117,427 shares of the company's stock worth $337,000 after buying an additional 6,400 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of Definitive Healthcare during the 2nd quarter worth approximately $32,000. Creative Planning grew its position in shares of Definitive Healthcare by 41.7% during the 2nd quarter. Creative Planning now owns 28,628 shares of the company's stock worth $112,000 after buying an additional 8,428 shares during the period. Finally, Schonfeld Strategic Advisors LLC acquired a new stake in shares of Definitive Healthcare during the 4th quarter worth approximately $35,000. Institutional investors and hedge funds own 98.67% of the company's stock.

About Definitive Healthcare

Definitive Healthcare NASDAQ: DH is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company's flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source